

AstraZeneca AB  
SE-151 85 Södertälje, Sweden  
T: +46 8 553 260 00  
F: +46 8 553 290 00  
astrazeneca.com

## CERTIFICATION OF ENROLLMENT

**Study title:** A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

**EUCT number:** 2023-503357-35-00

(hereinafter referred to as "Study")

**Promoter:** AstraZeneca AB

(hereinafter referred to as "Promoter")

The Promoter of the Study declares that the Centre IRCCS ISMETT screened n°2 patients in 2025: 1 patient was a screening failure and 1 patient was enrolled in the study.

Date 11/03/2026

Name: Zosia Fedorowska; Associate Director, EPM (Study Leader)

Signature on behalf of the Promoter

*Zosia Fedorowska*  
Electronically signed by: Zosia Fedorowska  
Reason: I approve this document  
Date: 03-Apr-2026 13:47:16 GMT+2